Browsing by Subject "AngioVac"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Candida tropicalis endocarditis successfully treated with AngioVac and micafungin followed by long-term isavuconazole suppression
    (Elsevier, 2020-06-26) Prabhudas-Strycker, Kirsten K.; Butt, Saira; Reddy, Madhukanth T.; Medicine, School of Medicine
    We provide a review of current literature of native valve Candida tropicalis endocarditis. A 41-year old man presented with C. tropicalis candidemia complicated by superior vena cava mass and right main pulmonary artery thrombus. The patient achieved clinical and microbiologic cure with AngioVac of the mass and echinocandin for six weeks. Long-term suppression was challenging given the C. tropicalis strain was resistant to fluconazole, voriconazole and posaconazole. Additional susceptibilities were obtained and he remained relapse-free at 12 months with isavuconazole.
  • Thumbnail Image
    Item
    Percutaneous debulking of tricuspid vegetations due to infectious endocarditis in pregnancy: a case report
    (Elsevier, 2023-04-26) Boudova, Sarah; Casciani, Thomas; Weida, Jennifer; Obstetrics and Gynecology, School of Medicine
    Infective endocarditis is a rare but serious disease with increasing prevalence in women of childbearing age because of the opioid epidemic. Therefore, it is an increasingly frequent pregnancy complication. The gold standard of treatment is intravenous antibiotics with surgery reserved for refractory cases. However, pregnancy complicates decisions about the risk and timing of surgery. AngioVac represents a percutaneous alternative to surgical intervention. Here, we present a case of a 22-year-old G2P1001 woman with a history of intravenous drug use and infective endocarditis who continued to show signs and symptoms of septic pulmonary emboli despite management with intravenous antibiotics. The patient was deemed not to be a surgical candidate while pregnant and had an AngioVac procedure at 30 2/7 weeks of gestation with the removal of tricuspid vegetations. The patient was delivered via cesarean delivery at 32 5/7 weeks of gestation because of a nonreassuring fetal heart tracing. The patient's tricuspid valve was replaced on postpartum day 16. This case demonstrates that AngioVac can be safely used in the third trimester of pregnancy and may be considered in consultation with a multidisciplinary team for the management of infective endocarditis refractory to antibiotic treatment as an interim measure until surgery can be safely performed.